Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
Status:
Active, not recruiting
Trial end date:
2022-01-27
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and tolerability of atogepant in participants
with chronic migraine. This study includes a 12-week treatment period.